Delving into the Latest Updates on Neothetics, Inc. with Synapse

概览

关联

13

项与 Neothetics, Inc. 相关的临床试验

NCT03005717

/ Completed临床2期

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of LIPO-202 (Salmeterol Xinafoate for Injection) for the Reduction of Submental Subcutaneous Fat

Study LIPO-202-CL-31 is a multi center, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of two different doses of LIPO-202 versus placebo on submental bulging due to subcutaneous fat. Approximately 150 participants of either gender who have a "Moderate Bulge" or "Large Bulge" in the submental fat (on Patient-Reported Submental Bulging Scale [PR-SBS] and Clinician-Reported Submental Bulging Scale [CR-SBS]) will be recruited for this study.

开始日期2016-12-22

申办/合作机构

Neothetics, Inc.

NCT02568319

/ Completed临床2期

A Phase 2 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging in a Defined Special Population - Obese Subjects (BMI > or Equal to 30 kg/m2)

This is a multi-center, randomized, placebo-controlled, double-blind study evaluating the safety and efficacy of LIPO-202 for the reduction of central abdominal bulging in obese subjects.

开始日期2015-09-01

申办/合作机构

Neothetics, Inc.

NCT02483533

/ Terminated临床3期

A Double-Blind Extension Study to Evaluate the Post-Treatment Safety and Duration of Clinical Effect of LIPO-202 in Subjects Who Completed Either the LIPO-202-CL-18 or LIPO-202-CL-19 Study

LIPO-202-CL-23 is a follow-on study to evaluate the post-treatment safety and duration of clinical effect of LIPO-202 in subjects that completed either the LIPO-202-CL-18 (NCT02397499) or LIPO-202-CL-19 (NCT02398188). No risks related to treatment are anticipated as subjects will not receive additional treatment with LIPO-202 or Placebo for LIPO-202 in this follow-on study.

开始日期2015-06-01

申办/合作机构

Evofem, Inc.

[+1]

100 项与 Neothetics, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Neothetics, Inc. 相关的专利（医药）

登录后查看更多信息

1

项与 Neothetics, Inc. 相关的新闻（医药）

2011-04-04

·BioSpace

Lithera Appoints Thomas Wiggans to Board of Directors

SAN DIEGO, April 4, 2011 (GLOBE NEWSWIRE) -- Lithera, Inc. announced today the appointment of Thomas G. Wiggans to its Board of Directors."Lithera is making substantial progress with LIPO-102 by generating positive results with selective, non-ablative localized fat reduction," said George Mahaffey, President and Chief Executive Officer of Lithera. "These encouraging developments will allow us to enter the next stages of corporate development. I have worked closely with Tom before and believe that his experience in successfully building and leading dermatology companies will be of great value as we advance our programs."

IPO

100 项与 Neothetics, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Neothetics, Inc. 相关的转化医学

登录后查看更多信息